Monday, September 28, 2015
The number of mobile health applications available to consumers now surpasses 165,000, as developers incorporate innovative data collection features linked to sensors and wearables, according to a new report released by the IMS Institute for Healthcare Informatics. While most available apps focus on overall wellness, healthcare systems and professionals are expressing greater interest and excitement in broader app use as barriers to mainstream adoption of mHealth are removed—especially in the area of chronic disease management.
The Undiagnosed Diseases Network (UDN), a clinical research initiative of the National Institutes of Health, has opened an online patient application portal called the UDN Gateway. Introduction of this application system sets the stage for the network to advance its core mission: to diagnose patients who suffer from conditions that even skilled physicians have been unable to diagnose despite extensive clinical investigation. These diseases are difficult for doctors to diagnose because they are rarely seen, have not previously been described or are unrecognized forms of more common diseases.
Optimal Strategix Group (OSG), based in Newtown, Pa., has launched its CAVII app, available for download in the Apple App Store. CAVII is an iOS-based clinical study matching and analytics platform. Ushering in a new era of patient engagement, CAVII’s aim is to revolutionize clinical studies through the use of analytics for superior patient matching. Through CAVII, clinical studies could become more cost-effective, efficient and ultimately more engaging and insightful for patients and clinicians.
PeptiDream, a public Tokyo-based biopharmaceutical company, has announced a multi-target discovery and optimization collaboration with Sanofi. PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to generate macrocyclic/constrained peptides against multiple targets of interest selected by Sanofi. Sanofi will have the right to develop and commercialize all therapeutic peptides resulting from the collaboration.
BioClinica, a provider of integrated clinical research technology services, has created a new platform: the BioClinica eHealth App xChange. The exchange aims to provide healthcare payers, providers, researchers and regulators with an ecosystem of integrated mobile and cloud-based applications through its eHealth Cloud.
Thermo Fisher Scientific has launched two next-generation sequencing (NGS) systems designed to deliver a comprehensive solution that simplifies targeted sequencing. Built upon Ion Torrent technology, the new Ion S5 and Ion S5 XL benchtop systems provide scientists with rapid, cost-effective and flexible platforms that can be scaled for all research areas, including inherited disorders, infectious agents, microbial identification and translational cancer research.
A dozen awards from the NIH will support research that incorporates DNA sequence information into electronic medical records. The goal of research conducted by the Electronic Medical Records and Genomics (eMERGE) network is to better understand the genomic basis of disease and to tailor medical care to individual patients based on their genomic differences.
Icon, a global CRO, is working with IBM to help reduce the time and costs of drug development, while also offering patients enhanced quality-of-care by connecting them to relevant clinical trials. Icon will tap Watson’s cognitive computing power to help automate the cumbersome process of identifying patients who meet the criteria for a clinical trial, and to analyze protocols to assess trial feasibility and identify optimal trial sites.